anti-Thyroid Drugs
PreclinicalSmall molecule
anti-Thyroid Drugs is one of 10 small molecule programs targeting Hyperthyroidism. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Hyperthyroidism
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Carnitor
LLeadiant Biosciences, Inc.
Approved
Propanolol
WWeill Medical College of Cornell University
Approved
Tapazole
VViking Therapeutics, Inc.
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Potassium Iodide
DDawnrays Pharmaceutical (Holdings) Limited
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
Thiamine
UUniversiti Kebangsaan Malaysia Medical Centre
Preclinical
anti-Thyroid Drugs
SShandong Provincial Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-Thyroid Drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShandong Provincial Hospital